about
Shoulder pain and dysphagia with an unexpected cause.Severe cholestatic jaundice after a single administration of ajmaline; a case report and review of the literatureMicrobiome manipulation with faecal microbiome transplantation as a therapeutic strategy in Clostridium difficile infectionOptimized Sample Handling Strategy for Metabolic Profiling of Human Feces.Review article: depression and the use of antidepressants in patients with chronic liver disease or liver transplantation.Anticoagulation in chronic liver disease.Faecal microbiota transplant: a novel biological approach to extensively drug-resistant organism-related non-relapse mortality.National survey of practice of faecal microbiota transplantation for Clostridium difficile infection in the UK.Obstacles to establishing an NHS faecal transplant programme.Weight loss in a man from West Africa. S. stercoralis hyperinfection.Comparative epidemiology of Clostridium difficile infection: England and the USA.Letter: depression and the use of anti-depressants in patients with chronic liver disease or liver transplantation - authors' reply.Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: A randomized clinical trial.Gastrointestinal: Duodenal variceal bleeding secondary to thrombophilia-related portal vein thrombosis.Meeting update: faecal microbiota transplantation--bench, bedside, courtroom?Long term outcomes of initial infliximab therapy for inflammatory pouch pathology: a multi-Centre retrospective studyInhibiting Growth of Clostridioides difficile by Restoring Valerate, Produced by the Intestinal MicrobiotaFunctional microbiomics: Evaluation of gut microbiota-bile acid metabolism interactions in health and diseaseEffective fecal microbiota transplantation for recurrent Clostridioides difficile infection in humans is associated with increased signalling in the bile acid-farnesoid X receptor-fibroblast growth factor pathwayThe implementation of omics technologies in cancer microbiome research1171. Impact on Mortality, Length of Stay, and Antibiotic Use in Allogenic and Autologous Stem Cell Transplant Patients Colonized With Carbapenemase-Producing EnterobacteriaceaeThe use of faecal microbiota transplant as treatment for recurrent or refractory Clostridium difficile infection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelinesThe use of faecal microbiota transplant as treatment for recurrent or refractory Clostridium difficile infection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelinesThe application of omics techniques to understand the role of the gut microbiota in inflammatory bowel diseaseDerivation and validation of a cardiovascular risk score for prediction of major acute cardiovascular events in non-alcoholic fatty liver disease; the importance of an elevated mean platelet volumeCurrent and future pharmacological therapies for managing cirrhosis and its complicationsAntibiotic-Associated Disruption of Microbiota Composition and Function in Cirrhosis Is Restored by Fecal TransplantClostridium difficile infection and antibiotic-associated diarrhoeaLetter: improvements in mental health after faecal microbiota transplantation-an underexplored treatment-related benefit?Ursodeoxycholic acid enriches intestinal bile salt hydrolase-expressing Bacteroidetes in cholestatic pregnancyA randomised controlled study shows supplementation of overweight and obese adults with lactobacilli and bifidobacteria reduces bodyweight and improves well-beingInternational consensus conference on stool banking for faecal microbiota transplantation in clinical practiceNon-Alcoholic Fatty Liver Disease and Vascular DiseaseScreening of faecal microbiota transplant donors during the COVID-19 outbreak: suggestions for urgent updates from an international expert panelImmunotoxicity from checkpoint inhibitor therapy: clinical features and underlying mechanismsLetter: role of mean platelet volume levels in the prediction of major acute cardiovascular events in patients with non-alcoholic fatty liver disease-authors' replyAntibiotic therapy and outcome from immune-checkpoint inhibitorsFaecal microbiota transplant for eradication of multidrug-resistant Enterobacteriaceae: a lesson in applying best practice? Re: 'A five-day course of oral antibiotics followed by faecal transplantation to eradicate carriage of multidrug-resistant EnFecal Microbiota Transplantation in Patients With Primary Sclerosing Cholangitis: A Pilot Clinical TrialIntroduction to the joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) faecal microbiota transplant guidelines
P50
Q34707075-7EB14A1D-3543-4163-8529-32BD386931F1Q35138005-760EB783-7868-4EFF-9577-7AF93D4DB912Q35240464-84A20AC3-9DC2-462D-B1B3-4B2BCFB1225AQ35985878-735B48ED-23D4-4AFB-835C-B77289ECA1B7Q38245124-331D30AE-F809-42AA-85CE-F356F47F2F34Q38770377-CF12A05D-BBE7-44C7-BE3D-126DE453230BQ40132198-DCFF8EEC-C1C3-4A3A-A6DC-88445B4C0C83Q46455948-BAB83EDB-4387-4EBF-89FC-EDAB59DA9BD8Q46637075-30A49E8A-A7B3-412B-BBD7-CC46E9FAC6A2Q47397352-FD12B166-1D3C-4D12-95C3-21939B9901DFQ47809984-8D2EA109-CB06-4C47-8837-0AE04A570578Q48086309-66A1DAC3-B9D1-4305-9FF9-2315952B35B9Q48118701-F44D8949-DD0B-4A86-9D27-58767CD73408Q48160459-05816C17-4A06-473B-AE60-8A6D300B0651Q53081545-B3C5D384-D22C-473B-82EA-EB5346049B68Q57065686-338EC9C9-52CB-4ECA-9988-8650C41FB614Q57114650-F44ADFCF-1946-4168-B49B-FF13B2206759Q57120445-CD1EF9C7-70C7-4BD0-8D85-45D6CA8B9278Q57316740-3E1513FC-91D9-4AC8-BE74-1666F7AA4E7AQ58762649-82062225-A025-493C-B646-A2887B843628Q59328595-C6269315-418F-44C5-8E39-7C842FCC2398Q60174336-5050D5DA-C596-4C52-981D-F3BA2BDD9BF5Q60174340-B351FE92-C23E-4602-BE05-CC60C6A176DDQ61810839-B7C62ADD-0AB4-4DBB-86ED-0286C21E17CFQ64060477-8AC0BA4D-B51D-4689-A2C9-E6F1EA7E0FFCQ64093529-528A0413-903F-4A27-9AFF-F82E62CA3D53Q88723941-DB24AA09-065A-4BE9-BC2A-7999517AB98CQ88955138-DDC909D3-3F4A-43F2-8887-18EE531E966DQ89018291-7C1E2C43-483E-449D-AC6C-A933ECC5098FQ90010033-50C4A630-4AF0-438F-BE2E-54760D9E61CDQ90118101-394B61A6-D23C-469D-AC4C-9826278C9ECEQ90347940-FF610355-3045-445C-9BED-926ECE40FE3EQ90435399-9E236502-2EDF-4BC1-B498-E57486505A6EQ90465209-AE069A28-5124-4F20-8C77-98FDB60A9240Q90916342-C22B29E3-1A12-454F-9650-F7CAD13FE3C2Q90967041-892F400E-18B6-44A0-9002-6B43560AA98CQ91149803-58BB6292-5C74-4403-B636-C312A790BA9EQ91237459-275DCBBC-609C-471A-A141-1EB9C0FD7931Q91395849-9D9C6699-46CA-4F20-99AD-F6D8FC24F161Q91634587-80FBBAAC-F08E-4ACB-82A5-68A77DAF7766
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Benjamin Mullish
@ast
Benjamin Mullish
@en
Benjamin Mullish
@es
Benjamin Mullish
@nl
Benjamin Mullish
@sl
type
label
Benjamin Mullish
@ast
Benjamin Mullish
@en
Benjamin Mullish
@es
Benjamin Mullish
@nl
Benjamin Mullish
@sl
prefLabel
Benjamin Mullish
@ast
Benjamin Mullish
@en
Benjamin Mullish
@es
Benjamin Mullish
@nl
Benjamin Mullish
@sl
P1053
O-9524-2017
P106
P1153
37108064800
P21
P31
P3829
P3835
benjamin-mullish
P496
0000-0001-6300-3100